Quickfire Q&A delivers in-person insights from congresses, bringing together expert perspectives on the studies and data shaping clinical practice.
In this episode, recorded at the European Hematology Association (EHA) 2026 Congress, we speak to Nicola Conran, State University of Campinas (UNICAMP), Brazil, about the latest developments in sickle cell disease and the future of emerging therapies, including gene editing, targeted treatments, and approaches addressing inflammation.
Key topics discussed include:
- Gene therapy durability: The need for long-term follow-up and equitable access to transformative treatments.
- Treatment innovation: How new therapies targeting fetal haemoglobin and inflammation could reshape sickle cell care.
- Disease management: Why tackling inflammation and organ damage is key to improving patient outcomes.
- Future trials: The importance of broader endpoints beyond vaso-occlusive crisis reduction.
Disclosure: Conran has received grants or contracts from the São Paulo Research Foundation (FAPESP) and Novartis AG; and participated on a Data Safety Monitoring Board or Advisory Board for Novo Nordisk.
Read the latest issue of EMJ Hematology, published on 23rd July, for more expert insights and highlights from EHA 2026.
